Revance Therapeutics
RVNC
$3.32
Share price
-22.61%
Change (1 day)
-90.71%
Change (1 year)
Categories
Revance Therapeutics (RVNC) - Cash on Hand
Cash on Hand as of December 2023 : $0.25 B
According to Revance Therapeutics's latest financial reports the company has $0.25 B in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Revance Therapeutics - Cash on Hand chart (from 2012 to 2023)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2023-12-31 | $0.25 B | -25.47% |
| 2022-12-31 | $0.34 B | 51.38% |
| 2021-12-31 | $0.22 B | -48.44% |
| 2020-12-31 | $0.43 B | 50.46% |
| 2019-12-31 | $0.29 B | 65.01% |
| 2018-12-31 | $0.17 B | -37.85% |
| 2017-12-31 | $0.28 B | 52.48% |
| 2016-12-31 | $0.18 B | -26.47% |
| 2015-12-31 | $0.25 B | 47.52% |
| 2014-12-31 | $0.17 B | 4269.75% |
| 2013-12-31 | $3.91 M | -4.14% |
| 2012-12-31 | $4.08 M | -86.22% |
| 2011-12-31 | $29.62 M |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | $26.21 B | 10,225.50% | 🇺🇸 USA |
 Biogen BIIB | $1.07 B | 323.13% | 🇺🇸 USA |
 MediciNova MNOV | $50.99 M | -79.91% | 🇺🇸 USA |